Psychiatry AtlasMedication guide · United States

Medicine for Alzheimer’s dementia symptoms

Memantine (Namenda, Namenda XR, Namenda Titration Pak)

Generic name
memantine hydrochloride
Brand names
Namenda; Namenda XR; Namenda Titration Pak
Medication class
Medicine for Alzheimer’s dementia symptoms
Forms covered
Memantine immediate-release tablets; Memantine extended-release capsules

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Medication Safety Alerts

Look-alike / sound-alike name

Memantine treats symptoms of moderate-to-severe Alzheimer’s dementia. Immediate-release tablets and extended-release capsules have separate dosing instructions.

Namenda (historical brand); Namenda XR (historical brand); Namenda Titration Pak (historical brand).

What to expect: Treatment may help cognition and everyday functioning, but benefit varies and may be modest.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Moderate-to-severe Alzheimer’s dementia — Adults. Symptomatic treatment; no evidence that it prevents or slows neurodegeneration.Memantine immediate-release tablets; Memantine extended-release capsules.

What should I expect?

Treatment may help cognition and everyday functioning, but benefit varies and may be modest. Memantine has not been shown to stop or reverse the underlying disease.

The dose is usually increased gradually over several weeks. A caregiver can help track daily abilities, constipation, dizziness and falls; review benefit and tolerability at follow-up rather than expecting immediate memory restoration.

How do I take it safely?

Take with or without food according to the prescribed IR or ER schedule. ER capsules may be swallowed whole or opened onto applesauce; swallow the entire contents without chewing. Do not crush, divide or chew the ER dose.

Kidney function determines whether a lower dose is needed. Review severe liver disease, seizures, urinary problems or severe urinary infection with the clinician.

Have sodium bicarbonate, medicines that change urine acidity, amantadine, ketamine and dextromethorphan-containing cough medicines reviewed. Limited liver metabolism does not mean there are no interactions.

Follow cognition, daily activities, bowel symptoms, dizziness and falls. Caregiver or pharmacy support can help prevent duplicate doses or confusion between IR and ER products.

Skip a single missed dose and take the next on schedule. Never double. After several missed days, contact the prescriber because a lower restart dose and retitration may be needed.

Plan stopping or changing products with the treating team. A memantine/donepezil combination adds a second medicine’s precautions. Pregnancy, breastfeeding and pediatric safety are not established.

Do not use after a known memantine or ingredient allergy.

What side effects should I know about?

  • Dizziness, headache, confusion and constipation with immediate-release treatment.
  • Headache, diarrhea and dizziness with extended-release treatment.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Contact the clinician promptly for severe new confusion, hallucinations, marked sleepiness, unsteadiness or repeated falls.
  • Get emergency help for trouble breathing, swelling of the tongue or throat, collapse, a seizure or inability to wake. Suspected overdose needs immediate poison-center or emergency advice; do not wait for symptoms.

What else should I know to stay safe?

  • Do not use after memantine or ingredient allergy. Severe kidney impairment requires a lower dose; review severe liver disease, seizures, urinary problems and severe urinary infection. Monitor daily functioning, dizziness, constipation and falls.
  • Have sodium bicarbonate, medicines that change urine acidity, amantadine, ketamine and dextromethorphan-containing cough medicines checked. A memantine/donepezil combination adds a second medicine’s precautions.
  • After several days without treatment, ask before restarting because a lower dose and retitration may be needed. Plan stopping or switching with the treating team. Pregnancy, breastfeeding and pediatric safety are not established.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • The IR and ER numbers are different for a reason: they are distinct regimens, not a simple milligram-for-milligram exchange.
  • Kidney function can matter more than age alone when choosing the dose.
  • Some cough medicines and even products that change urine acidity can interact. Include nonprescription products in the medication list.

How does it work?

Memantine changes the activity of NMDA receptors, receiving proteins that respond to glutamate, a chemical messenger used by brain cells. These receptors control tiny channels through which electrically charged particles can move. Memantine can block an open channel, an action thought to contribute to symptom benefit, although the full explanation remains uncertain.

Explore more in Brain & Science: NMDA Receptors: Memantine.

How was this medicine developed?

Namenda tablets received FDA approval in 2003, and Namenda XR followed in 2010. Memantine offered a different approach from medicines that prevent acetylcholine breakdown, while remaining a treatment for symptoms rather than a cure.

How do I say the name?

Memantine: MEM-an-teen. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Memantine immediate-release tablets: current generic prescribing information
  2. Memantine ER capsules: current generic prescribing information
  3. Namenda tablets: FDA approval and discontinued brand status
  4. Memantine: patient information and historical brands
  5. Namenda XR: FDA approval and discontinued brand status
  6. Namenda immediate-release tablets: FDA prescribing information
  7. Memantine: Package Insert / Prescribing Information / MOA
  8. Namenda XR: FDA prescribing information
  9. Galantamine: current prescribing information
  10. Memantine: verified neutral parent, PubChem CID 4054
  11. ISMP List of Confused Drug Names
  12. Schizophrenia
  13. NIMH: Understanding psychosis

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top